BALTIMORE and NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Ahead of the first-ever Big Bets for America convening in Oklahoma City, The Rockefeller Foundation and Center for Civic Futures (CCF) today ...
Scholar Rock anticipates resubmitting the BLA and launching apitegromab in the U.S. in 2026, contingent on FDA reinspection results. The company expects to submit an sBLA for the second fill/finish ...
CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three core priorities: “First ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback